A Research Study Comparing a New Medicine Oral Semaglutide to Sitagliptin in People With Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1441 participants.

Also called NCT04017832

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,441 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT04017832
  • EudraCT 2018-002589-38
Other papers using this trial's data
  • Efficacy and safety of oral semaglutide vs sitagliptin in a predominantly Chinese population with type 2 diabetes uncontrolled with metformin: PIONEER 12, a double-blind, Phase IIIa, randomised trial Diabetologia, 2024-09 DOI, PubMed 38985161, PMC11410852 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Algeria, Brazil, China, Czechia, Hong Kong SAR China, Romania, Serbia, South Africa, Taiwan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04017832. Randomized; quadruple masking; primary purpose treatment. Start 2019-07-29 (actual); primary completion 2021-10-27 (actual). Results posted on 2023-09-29.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Research Study Comparing a New Medicine Oral Semaglutide to Sitagliptin in People With Type 2 Diabetes
Acronym
PIONEER 12
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Oral semaglutide
Intervention (Drug)
Sitagliptin
Intervention (Drug)
Placebo (oral semaglutide)
Intervention (Drug)
Placebo (sitagliptin)
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct04017832
Content hash
f7b33b715aac77d43ccbcef81d626e42c0ef42a4d4d2c6c35547ae1f828a4df5